6GXQ

Crystal structure of T. brucei PDE-B1 catalytic domain with inhibitor NPD-1335

Summary for 6GXQ

• Entry DOI: 10.2210/pdb6gxq/pdb
• Descriptor: Phosphodiesterase, MAGNESIUM ION, ZINC ION, ... (7 entities in total)
• Functional Keywords: parasitic phosphodiesterase, hydrolase, african trypanosomiasis, sleeping sickness
• Biological source: Trypanosoma brucei
• Total number of polymer chains: 2
• Total formula weight: 82453.29

Authors

Singh, A.K.,Brown, D.G. (deposition date: 2018-06-27, release date: 2019-07-10, Last modification date: 2024-01-17)

Primary citation

de Heuvel, E.,Singh, A.K.,Boronat, P.,Kooistra, A.J.,van der Meer, T.,Sadek, P.,Blaazer, A.R.,Shaner, N.C.,Bindels, D.S.,Caljon, G.,Maes, L.,Sterk, G.J.,Siderius, M.,Oberholzer, M.,de Esch, I.J.P.,Brown, D.G.,Leurs, R.
Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors (Part 2).
Bioorg.Med.Chem., 27:4013-4029, 2019

PubMed Abstract: Inhibitors against Trypanosoma brucei phosphodiesterase B1 (TbrPDEB1) and B2 (TbrPDEB2) have gained interest as new treatments for human African trypanosomiasis. The recently reported alkynamide tetrahydrophthalazinones, which show submicromolar activities against TbrPDEB1 and anti-T. brucei activity, have been used as starting point for the discovery of new TbrPDEB1 inhibitors. Structure-based design indicated that the alkynamide-nitrogen atom can be readily decorated, leading to the discovery of 37, a potent TbrPDEB1 inhibitor with submicromolar activities against T. brucei parasites. Furthermore, 37 is more potent against TbrPDEB1 than hPDE4 and shows no cytotoxicity on human MRC-5 cells. The crystal structures of the catalytic domain of TbrPDEB1 co-crystalized with several different alkynamides show a bidentate interaction with key-residue Gln874, but no interaction with the parasite-specific P-pocket, despite being (uniquely) a more potent inhibitor for the parasite PDE. Incubation of blood stream form trypanosomes by 37 increases intracellular cAMP levels and results in the distortion of the cell cycle and cell death, validating phosphodiesterase inhibition as mode of action.

PubMed: 31378593
DOI: 10.1016/j.bmc.2019.06.026

Experimental method

X-RAY DIFFRACTION (1.96 Å)